Dr. Margaux Bennett, Ph.D., joined Kronos Bio in May 2021 and serves as Vice President, Corporate Development and Investor Relations.  Margaux has led the business development function and played a lead role in financial and strategic planning since joining, and in November of 2023 she took over the investor relations function. For our Genentech collaboration announced in January 2023, she drove the creation of critical deliverables, cultivated cross-company relationships, and demonstrated the tenacity needed to close the deal. Margaux’s strengths in cross-functional collaboration and strategic planning have led to key strategic and operational decisions across the portfolio.   

Prior to her tenure at Kronos Bio, Margaux established herself as a strategy and business development professional at Acadia Pharmaceuticals. While at Acadia, she identified and closed the first deal for the company by in-licensing trofinetide as a Phase 3 ready asset in 2018, which was approved as DAYBUE in 2023 as the first approved therapy for Rett Syndrome. In addition to crafting the scientific and business case for in-bound assets, she played a key role in laying out and refining the life cycle management plan for Acadia’s lead asset NUPLAZID across indications.   

Margaux began her career as a management consultant at Deloitte, working with life sciences Monitor Deloitte team to provide strategic advice to small and mid-cap life sciences companies. She holds a Ph.D. in Molecular and Cell Biology from UC Berkeley where her thesis focused on the role of microRNAs in MYC driven oncogenesis. As our VP, Corporate Development and Investor Relations, Margaux’s ability to communicate across science and business functions positively positions Kronos Bio to secure the partnerships and funding needed to maximize the value of our science.